Therapeutics News and Research

RSS

Georgia State University researchers develop a method to better trace and treat cancer

A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed by Georgia State University researchers.

18 Nov 2015

Scientists identify mechanism that may help prostate cancer cells escape effects of cancer drugs

Advanced prostate cancer is a disease notoriously resistant to treatment. New research by scientists at Fred Hutchinson Cancer Research Center and the University of California, San Francisco sheds light on a new mode of drug resistance to emerging therapies in metastatic prostate cancer.

18 Nov 2015

TSRI scientists discover first-in-class compounds that target persistent tuberculosis

Tuberculosis has been infecting humans for several millennia, making it one of the most horribly successful diseases in history. Today, it is still a major killer, responsible for some 1.5 million deaths each year.

18 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

Researchers use large-scale computer modeling to show effects of confinement on cell macromolecules

Using large-scale computer modeling, researchers have shown the effects of confinement on macromolecules inside cells -- and taken the first steps toward simulating a living cell, a capability that could allow them to ask 'what-if' questions impossible to ask in real organisms.

17 Nov 2015

Researchers identify molecular patterns that dominate gene expression in the human brain

The human brain may be the most complex piece of organized matter in the known universe, but Allen Institute researchers have begun to unravel the genetic code underlying its function. Research published this month in Nature Neuroscience identified a surprisingly small set of molecular patterns that dominate gene expression in the human brain and appear to be common to all individuals, providing key insights into the core of the genetic code that makes our brains distinctly human.

17 Nov 2015

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD).

15 Nov 2015

CASI reports net loss of $1.6 million for third quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and nine months ended September 30, 2015.

13 Nov 2015

CHOP researchers delay symptoms, extend lifespan in animal model of Batten disease

Researchers have taken a significant step forward in developing gene therapy against a fatal neurodegenerative disease that strikes children. By delivering a working version of a gene to produce a key enzyme that is lacking in Batten disease, the scientists delayed symptoms and extended lifespan in dogs with a comparable disease.

12 Nov 2015

Mike and Alice Jackson announce $1 million pledge to support NSU's cancer research

For Mike and Alice Jackson, cancer is personal; so much so that they are joining with Nova Southeastern University researchers in the fight against one of the nation's deadliest diseases. The Jacksons announced today a $1 million personal pledge to support NSU's cancer research.

12 Nov 2015

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma.

11 Nov 2015

Research may offer new treatments for patients suffering from severe diarrhea

Everyone has suffered from it. It's ranged from mild to severe. It's a condition that's most-often described in a whisper.

11 Nov 2015

Juniper Pharmaceuticals’ third quarter product revenues increase 22% to $7.2 million

Juniper Pharmaceuticals, Inc., a women's health therapeutics company, today announced financial results for the three months ended September 30, 2015.

11 Nov 2015

Betalin launches new EMP technology that could transform diabetes treatment

Betalin Therapeutics, a biotech company specializing in tissue engineering for curing diabetes, introduces the Engineered Micro Pancreas (EMP), a novel technology that provides significant levels of glucose-regulated insulin secretion over extended periods of time.

11 Nov 2015

New findings reveal association between colorectal cancer and melanoma drug treatment

Veteran cancer reseacher Prof. Emeritus Alexander Levitzki of Hebrew University of Jerusalem says new findings show link between colorectal cancer and melanoma drug treatment knoqwn as "NT157" in two recently published studies in journal, "Ocogene."

10 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Astellas enters into definitive agreement to acquire Ocata

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

Therapeutics News and Research

Georgia State University researchers develop a method to better trace and treat cancer

Scientists identify mechanism that may help prostate cancer cells escape effects of cancer drugs

TSRI scientists discover first-in-class compounds that target persistent tuberculosis

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Researchers use large-scale computer modeling to show effects of confinement on cell macromolecules

Researchers identify molecular patterns that dominate gene expression in the human brain

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

CASI reports net loss of $1.6 million for third quarter 2015

CHOP researchers delay symptoms, extend lifespan in animal model of Batten disease

Mike and Alice Jackson announce $1 million pledge to support NSU's cancer research

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Research may offer new treatments for patients suffering from severe diarrhea

Juniper Pharmaceuticals’ third quarter product revenues increase 22% to $7.2 million

Betalin launches new EMP technology that could transform diabetes treatment

New findings reveal association between colorectal cancer and melanoma drug treatment

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Astellas enters into definitive agreement to acquire Ocata

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Advancing therapeutic biopolymer development eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News